| Shao, Haibo |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT06632093: HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC |
|
|
| Recruiting | N/A | 84 | RoW | hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody | First Hospital of China Medical University | BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, Lenvatinib, PD-1, Systemic Therapy | 09/25 | 12/25 | | |
NCT06631326: HAIC in Combination with PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) |
|
|
| Recruiting | N/A | 228 | RoW | hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody | First Hospital of China Medical University | HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitors | 09/25 | 12/25 | | |
| Yang, Yefa |
NCT06712017: Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China |
|
|
| Enrolling by invitation | N/A | 100 | RoW | Yttrium-90 (Y-90) resin microspheres | GrandPharma (China) Co., Ltd. | Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable | 12/24 | 06/25 | | |
| Wang, Kui |
| Active, not recruiting | 2 | 43 | RoW | Pembrolizumab+Lenvatinib | Shanghai Zhongshan Hospital, Merck Sharp & Dohme LLC | Carcinoma, Hepatocellular | 12/23 | 07/25 | | |
NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 125 | US, RoW | YIV-906+Sorafenib, Placebo+Sorafenib | Yiviva Inc. | Advanced Hepatocellular Carcinoma | 12/23 | 05/24 | | |
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab+Lenvatinib | Shanghai Zhongshan Hospital, Sun Yat-sen University, Eastern Hepatobiliary Surgery Hospital | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
| He, Tian |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
